Skip to main content
PCNTinactive

Point of Care Nano-Technology, Inc.

Biological products·Commercial

PCNT evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for PCNT—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

3.7/10

BioSniper Score

Based on 4 of 6 signals

Market Cap

Cash Runway

3.4 mo

Lead Asset

ez saliva (Approved)

Next Catalyst

Financial data as of Apr 30, 2024.

Tracking 1 pipeline candidate for Point of Care Nano-Technology, Inc..

Run Point of Care Nano-Technology, Inc. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Point of Care Nano-Technology, Inc. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 4 of 6 signals · derived from public data

Cash Runway0.9

3.4 months

Financial Health0.5

OCF -$261 · Net income -$5K

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Runway

Pipeline

Financials

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.